JP Patent

JP6945614B2 — 経鼻投与

Assigned to Optinose AS · Expires 2021-10-06 · 5y expired

What this patent protects

Patent listed against Cutivate.

Drugs covered by this patent

Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm

Patent Metadata

Patent number: JP6945614B2
Jurisdiction: JP
Classification: —
Expires: 2021-10-06
Drug substance claim: No
Drug product claim: No
Assignee: Optinose AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.